Sergio Iannazzo
4PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Apr 20, 2024
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.Cécile van Steen, Lorenzo Celico, Erik Spaepen
|Jun 07, 2019
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.Carsten Hirt, Sergio Iannazzo, Silvia Chiroli
|Aug 09, 2018
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.Moshe Yair Levy, Lisa J McGarry, Hui Huang
|Oct 17, 2017
Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.Sergio Iannazzo, Ange-Christelle Iliza, Louise Perrault
Pageof 1
